← All trials
NCT03530930
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2018
- Primary completion
- Sep 30, 2018
- Completion date
- Sep 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical ImmunologyLead sponsor
- Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical ImmunologyReponsible party - principal investigator
- Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical ImmunologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.